Drug Landscape ›
PEG-Asparaginase ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 127
Most-reported reactions
Hypotension — 18 reports (14.17%) Sepsis — 17 reports (13.39%) Febrile Neutropenia — 15 reports (11.81%) Off Label Use — 12 reports (9.45%) Vomiting — 12 reports (9.45%) Alanine Aminotransferase Increased — 11 reports (8.66%) Headache — 11 reports (8.66%) Pyrexia — 11 reports (8.66%) Encephalopathy — 10 reports (7.87%) Thrombosis — 10 reports (7.87%)
Source database →
PEG-Asparaginase in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is PEG-Asparaginase approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for PEG-Asparaginase in United States?
Dana-Farber Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.